Biomarkers. What is Their Benefit in the Identification of Infection, Severity Assessment, and Management of Community-acquired Pneumonia?

Infectious Disease Clinics of North America

Volumn 27, Issue 1, 2013, Pages 19-31

  Upadhyay, Shweta ^a   Niederman, Michael S ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Biomarkers; C reactive protein; Community acquired pneumonia; Duration of therapy; Procalcitonin; Severity of illness

Indexed keywords

ADRENOMEDULLIN; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; CLINICAL ASSESSMENT; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; EMPYEMA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; MORTALITY; NEEDS ASSESSMENT; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTIVE VALUE; PROGNOSIS; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84873528481     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.11.003     Document Type: Review

References (48)

1. Kochanek KD, Xu J, Murphy SL, et al. Deaths: preliminary data for 2009. National Vital Statistics Reports; 59. No.4. CDC2011. Available at: . Accessed June 30, 2011. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_04.pdf.
2. Heron MP, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. National Vital Statistics Reports; 57. 2009. Available at: . Accessed July 10, 2011. http://www.cdc.gov/nchs/fastats/pneumonia.htm.
3. Welte T., Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Crit Care Med 2009, 30:127-135.
4. Restrepo M.I., Mortensen E.M., Rello J., et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010, 137:552-557.
5. Polgreen P.M., Chen Y.Y., Cavanaugh J.E., et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol 2007, 28:212-214.
6. Niederman M.S. Biological markers to determine eligibility in trials for community acquired pneumonia: a focus on procalcitonin. Clin Infect Dis 2008, 47:S127-S132.
7. Menendez R., Martinez R., Reyes S., et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009, 64:587-591.
8. Christ Crain M., Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Euo Respir J 2007, 30:556-573.
9. Almirall J., Bolibar I., Toran P., et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
10. Christ-Crain M., Jaccard-Stolz D., Bingisser R., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. Lancet 2004, 363:600-607.
11. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
12. Schuetz P., Christ Crain M., Thomann R., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
13. Muller B., Harbarth S., Stolz D., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, 7:10.
14. Stolz D., Christ-Crain M., Gencay M.M., et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly 2006, 136:434-440.
15. Holm A., Nexoe J., Bistrup L.A., et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract 2007, 57:547-554.
16. Jereb M., Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr 2006, 118:170-174.
17. Krüger S., Ewig S., Papassotiriou J., et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP - results from the German competence network CAPNETZ. Respir Res 2009, 10:65. 10.1186/1465-9921-10-65.
18. Ingram P.R., Inglis T., Moxon D., et al. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med 2010, 36:528-532.
19. Müller F., Christ-Crain M., Bregenzer T., et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010, 138:121-129.
20. Krüger S., Ewig S., Kunde J., et al. Pro-vasopressin (copeptin) in patients with community-acquired pneumonia - influence of antibiotic pre-treatment: results from the German competence network CAPNETZ. J Antimicrob Chemother 2009, 64:159-162.
21. El-Solh A.A., Vora H., Knight P.R., et al. Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes. Crit Care Med 2011, 39:1251-1256.
22. Niederman M.S. Distinguishing chemical pneumonitis from bacterial aspiration: still a clinical determination. Crit Care Med 2011, 39:1543-1544.
23. Niederman M.S. Making sense of scoring systems in community acquired pneumonia. Respirology 2009, 14:327-335.
24. Kaplan V., Clermont G., Griffin M.F., et al. Pneumonia: still the old man's friend?. Arch Intern Med 2003, 163:317-323.
25. Masia M., Gutierrez F., Shum C., et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005, 128:2223-2229.
26. Boussekey N., Leroy O., Alfandari S., et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006, 32:469-472.
27. Lacoma A., Rodriguez N., Prat C., et al. Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2012, 31:825-833.
28. Yende S., D'Angelo G., Kellum J.A., et al. Inflammatory markers at hospital discharge predicts subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008, 177:1242-1247.
29. Menendez R., Cavalcanti M., Reyes S., et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008, 63:447-452.
30. Reade M.C., Yende S., D'Angelo G., et al. Differences in immune response may explain lower survival among older men with pneumonia. Crit Care Med 2009, 37:1655-1662.
31. Kruger S., Ewig S., Giersdorf S., et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010, 182:1426-1434.
32. Ramirez J., Aliberti S., Mirsaeidi M., et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008, 47:182-187.
33. Musher D.M., Rueda A.M., Kaka A.S., et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007, 45:158-165.
34. Koivula I., Sten M., Makela P.H. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999, 159:1550-1555.
35. Hohenthal U., Hurme S., Helenius H., et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect 2009, 15:1026-1032.
36. Krüger S., Ewig S., Marre R., et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia. Eur Respir J 2008, 31:349-355.
37. Hirakata Y., Yanagihara K., Kurihara S., et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008, 61:170-174.
38. Park J.H., Wee J.H., Choi S.P., et al. The value of procalcitonin level in community-acquired pneumonia in the ED. Am J Emerg Med 2012, 36:1248-1254.
39. Coelho L.M., Salluh J.I., Soares M., et al. Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care 2012, 16:R53.
40. Christ-Crain M., Opal S.M. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010, 14:203.
41. Bello S., Lasierra A., Minchole E., et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012, 39:1144-1155.
42. Ramirez P., Ferrer M., Marti V., et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011, 39:2211-2217.
43. Huang D.T., Weissfeld L.A., Kellum J.A., et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008, 52:48-58.
44. Huang D.T., Angus D.C., Kellum J.A., et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009, 136:823-831.
45. Torres A., Ramirez P., Montull B., et al. Biomarkers and community-acquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med 2012, 33:266-271.
46. Bouadma L., Luyt C.E., Tubach F., et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474.
47. Schuetz P., Chiappa V., Briel M., et al. Procalcitonin algorithms for antibiotic therapy decisions, a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011, 171:1322-1331.
48. Schuetz P., Briel M., Christ-Crain M., et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012, 55:651-662.